Glaxo’s patent for Zantac’s active ingredient ... with the exception of Delaware where the majority of the cases are pending.

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and ... will approach the end of its patent life.

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ...

Amgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a patent blocking Sanofi from marketing its rival injected cholesterol drug in the country.

Last year, Yeda Research and Development, the tech transfer office of the Weizmann Institute, sued ImClone and Sanofi-Aventis over the Erbitux patent. (The patent was owned by the latter and licensed ...